Journal of hypertension
-
Journal of hypertension · Jun 2015
4A.01: LONG-TERM EFFECTS OF RENAL ARTERY DENERVATION IN REAL WORLD PATIENTS WITH UNCONTROLLED HYPERTENSION FROM THE GLOBAL SYMPLICITY REGISTRY.
The Global SYMPLICITY Registry (GSR) provides real world experience regarding the effects of radiofrequency denervation of the renal artery nerves in patients with uncontrolled hypertension. These data in hypertensive patients with a high proportion of concomitant conditions also characterized by sympathetic nervous system will further characterize the effects of renal denervation across a diverse patient population. ⋯ Renal denervation in a large real world population resulted in significant blood pressure reductions 1 year post-procedure. There were no long-term safety concerns following the denervation procedure. These data, including analysis of the BP-lowering effects of RDN in select subgroups, will be updated with two year follow-up of approximately 600 patients in June.
-
Journal of hypertension · Jun 2015
Principles of cerebral hemodynamics when intracranial pressure is raised: lessons from the peripheral circulation.
The brain is highly vascular and richly perfused, and dependent on continuous flow for normal function. Although confined within the skull, pressure within the brain is usually less than 15 mmHg, and shows small pulsations related to arterial pulse under normal circumstances. Pulsatile arterial hemodynamics in the brain have been studied before, but are still inadequately understood, especially during changes of intracranial pressure (ICP) after head injury. ⋯ The findings emphasize importance of reducing ICP, when raised, and on the additional benefits of reducing wave reflection from the lower body.
-
Journal of hypertension · Jun 2015
8B.04: RENAL ARTERY DENERVATION FOR TREATMENT OF HYPERTENSIVE PATIENTS WITH OR WITHOUT OBSTRUCTIVE SLEEP APNEA AND RESISTANT HYPERTENSION: RESULTS FROM THE GLOBAL SYMPLICITY REGISTRY.
Obstructive sleep apnea (OSA) is associated with sympathetic nervous system activation and the development of hypertension. The Global SYMPLICITY Registry is prospectively enrolling real world patients with uncontrolled hypertension including patients with OSA. This analysis compares baseline characteristics and blood pressure (BP) lowering effects of renal denervation in patients with and without OSA. ⋯ Renal denervation resulted in significant 6-month BP reductions in patients with and without OSA but there was not a significant difference in the BP change between the 2 groups. Data from a larger cohort of 2100 patients will be presented.
-
Journal of hypertension · Jun 2015
1C.01: SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A PROGNOSTIC MARKER OF ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN A BLACK POPULATION.
Elevated inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are well-known risk factors for cardiovascular mortality. The less familiar marker, soluble urokinase plasminogen activator receptor (suPAR), is known to predict cancer, infections and all-cause mortality. We determined whether suPAR, CRP and IL-6 are predictive of both all-cause and cardiovascular mortality in a black population, highly burdened by cardiovascular disease and HIV infection. ⋯ : SuPAR predicted both all-cause and cardiovascular mortality, independent of traditional risk factors, HIV and other inflammatory markers, underlining the prognostic value of suPAR in a black population.
-
Journal of hypertension · Jun 2015
4A.09: SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH SEVERE UNCONTROLLED HYPERTENSION: 12 MONTH RESULTS FROM THE ENLIGHTN II STUDY.
Percutaneous sympathetic renal artery denervation is available for the treatment of patients with resistant hypertension. We further investigated the safety and efficacy of a multi-electrode renal denervation system (EnligHTN™) in patients with severe uncontrolled hypertension. ⋯ In this real world, post-marketing study we demonstrate that multi-electrode renal denervation results in durable, highly significant and safe lowering of both office BP and ambulatory BP parameters in patients with severe uncontrolled hypertension up to 12 months following treatment.